Striving Together, Upgrading the Biopharma Industry – International Biopharma Industry Week Shanghai 2022 Kicks Off
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- On November 14, the opening ceremony of the second "International Biopharma Industry Week Shanghai" (hereinafter referred to as the "IBIWS 2022") took place in the Shanghai Zhangjiang Science Hall. Themed on "Striving Together, Upgrading the Biopharma Industry", the IBIWS 2022 will last five days with 1 opening ceremony and about 40 parallel events,...
WuXi Vaccines Establishes New Vaccines CDMO Facility in China
SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Vaccines. The 8,500-square-meter facility includes multiple 250L, 500L and 1000L single-use bioreactors as well as sterile drug-product...
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES’ “IDEAS TO IND” PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. The new subsidiary will leverage Harbour BioMed's technology platforms, including its Harbour Mice® and...
Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory
ZHUHAI, China, Nov. 15, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheus' EGFR/MET bispecific antibody (also known as PM1080) in Greater China, including Mainland China, Hong Kong, Macao and Taiwan....
C&R Research, the Largest Korean CRO, Expands Partnership with Medidata to Enhance Their Clinical Operations
C&R Research is the only CRO that authorized to Rave CTMS in Korea Sponsors targeting global markets will manage clinical operations with these solutions that effectively support multinational clinical trials. SEOUL, South Korea, Nov. 15, 2022 /PRNewswire/ -- Medidata, a Dassault Systèmes company, today announced that C&R Research, the largest Korean...
VentureBlick Launches Global Search for Healthcare Startups ‘Most Endorsed by the Medical Community’
SINGAPORE, Nov. 15, 2022 /PRNewswire/ -- VentureBlick, a fundraising platform matching healthcare startups with medical investors, has launched its worldwide search to identify promising healthcare startups for the medical community to evaluate, advise, and fund. Only startups that receive endorsement from a large group of medical professionals with relevant domain expertise will...
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy
-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients in China -- China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country -- Nefecon is approved in the U.S. and E.U., and received Breakthrough Therapy...
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, today announced that the first participant has been successfully dosed in a phase 3 clinical trial (GLORY-1) of mazdutide (Innovent...
First “Global State of Digital Health Report” Tapping into 200 Million Data Points Examining over 12,000 Digital Health Ventures Released At HLTH
Global Digital Health Intelligence Company Galen Growth and Integrated Marketing Agency FINN Partners Release Breaking Report for Free Download Report Will Guide C-Suite Entrepreneurs and Private Equity Investment Strategies NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Galen Growth, the leading digital health, data-driven market intelligence company, and FINN Partners, an independent global integrated marketing...
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly half are undiagnosed1 The LumiraDx HbA1c test is designed to address...
